← Browse by Condition
Medical Condition

cardiac amyloidosis

Total Trials
7
Recruiting Now
7
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for cardiac amyloidosis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — cardiac amyloidosis Clinical Trials

How many clinical trials are currently recruiting for cardiac amyloidosis?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for cardiac amyloidosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for cardiac amyloidosis?
cardiac amyloidosis research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a cardiac amyloidosis clinical trial?
Eligibility criteria for cardiac amyloidosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Centro Cardiologico Monzino 1 trial
Far Eastern Memorial Hospital 1 trial
Tianjin Medical University 1 trial
Mayo Clinic 1 trial
Leiden University Medical Center 1 trial

Recruiting Clinical Trials

NCT06799273
Recruiting
MECKI-Amyloidosis: Assessment of the Exercise Capacity and Prognosis of Patients with Cardiac Amyloidosis
Enrollment
1,400 pts
Location
Italy
Sponsor
Centro Cardiologico Monzino
View Trial →
NCT05593679
Recruiting
A Multi-center Cardiac PYP Scan Registry in Taiwan
Enrollment
1,000 pts
Location
Taiwan
Sponsor
Far Eastern Memorial Hospital
View Trial →
NCT07130565
Recruiting
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
Enrollment
500 pts
Location
China
Sponsor
Tianjin Medical University
View Trial →
NCT07308704
Recruiting
A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation
Enrollment
10,040,000 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06894290
Recruiting
International Cardiac Amyloidosis Registry
Enrollment
300 pts
Location
Belgium, Italy, Japa...
Sponsor
Leiden University Medical Cent...
View Trial →
NCT06458374
Recruiting
ATTR Cardiac Amyloidosis in a Selected Population
Enrollment
180 pts
Location
Norway
Sponsor
Helse Møre og Romsdal HF
View Trial →
NCT07336394
Recruiting
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
Enrollment
1,000 pts
Location
China
Sponsor
Chinese Academy of Medical Sci...
View Trial →

Related Conditions

heart failure (1) amyloid (1) amyloidosis (1) cardiomyopathy (1) ischemic heart disease (1) attr amyloidosis wild type (1) attr gene mutation (1) carpal tunnel syndrome (1) danon disease (1) fabry disease (1) noonan syndrome (1) cardiac sarcoidosis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology